Evidence map›Paper›PMID 21258134›Full record

ArticleThe Journal of biological chemistry2011

Reversible high affinity inhibition of phosphofructokinase-1 by acyl-CoA: a mechanism integrating glycolytic flux with lipid metabolism.

Christopher M Jenkins, Jingyue Yang, Harold F Sims, Richard W Gross

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. F26BP enables control of glycolysis rate independent of energy state.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Phosphofructokinase-1 in Cancer: A Promising Target for Diagnosis and Therapy.Recent patents on anti-cancer drug discovery · 2025
    Review
  10. Article
  11. Electro-metabolic signaling.The Journal of general physiology · 2024
    Article
  12. Cardiac Metabolism, Reprogramming, and Diseases.Journal of cardiovascular translational research · 2024
    Review
  13. Animals : an open access journal from MDPI · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. A nexus of lipid andFrontiers in endocrinology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Christopher M JenkinsDivision of Bioorganic Chemistry and Molecular Pharmacology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Jingyue Yang
Harold F Sims
Richard W Gross
Institute of Bioorganic Chemistry · BY

Funding

Regulation of lipid metabolism in diabetic myocardiumP01HL057278 · NHLBI · WASHINGTON UNIVERSITY · PI GROSS, RICHARD W · 1996 to 2012
$21.8M
LIPID MEDIATORS OF SIGNAL TRANSDUCTION IN SMOOTH MUSCLER01HL041250 · NHLBI · WASHINGTON UNIVERSITY · PI GROSS, RICHARD W · 1988 to 2011
$3.6M
NHLBI NIH HHS 5P01HL57278NHLBI NIH HHS P01 HL057278NHLBI NIH HHS R01 HL041250NHLBI NIH HHS R01HL41250
6 · The paper itself

Abstract

The enzyme phosphofructokinase-1 (PFK-1) catalyzes the first committed step of glycolysis and is regulated by a complex array of allosteric effectors that integrate glycolytic flux with cellular bioenergetics. Here, we demonstrate the direct, potent, and reversible inhibition of purified rabbit muscle PFK-1 by low micromolar concentrations of long chain fatty acyl-CoAs (apparent Ki∼1 μM). In sharp contrast, short chain acyl-CoAs, palmitoylcarnitine, and palmitic acid in the presence of CoASH were without effect. Remarkably, MgAMP and MgADP but not MgATP protected PFK-1 against inhibition by palmitoyl-CoA indicating that acyl-CoAs regulate PFK-1 activity in concert with cellular high energy phosphate status. Furthermore, incubation of PFK-1 with [1-(14)C]palmitoyl-CoA resulted in robust acylation of the enzyme that was reversible by incubation with acyl-protein thioesterase-1 (APT1). Importantly, APT1 reversed palmitoyl-CoA-mediated inhibition of PFK-1 activity. Mass spectrometric analyses of palmitoylated PFK-1 revealed four sites of acylation, including Cys-114, Cys-170, Cys-351, and Cys-577. PFK-1 in both skeletal muscle extracts and in purified form was inhibited by S-hexadecyl-CoA, a nonhydrolyzable palmitoyl-CoA analog, demonstrating that covalent acylation of PFK-1 was not required for inhibition. Tryptic footprinting suggested that S-hexadecyl-CoA induced a conformational change in PFK-1. Both palmitoyl-CoA and S-hexadecyl-CoA increased the association of PFK-1 with Ca2+/calmodulin, which attenuated the binding of palmitoylated PFK-1 to membrane vesicles. Collectively, these results demonstrate that fatty acyl-CoA modulates phosphofructokinase activity through both covalent and noncovalent interactions to regulate glycolytic flux and enzyme membrane localization via the branch point metabolic node that mediates lipid flux through anabolic and catabolic pathways.

Indexed as

Acyl Coenzyme AAnimalsCalciumCalmodulinElectrophoresis, Polyacrylamide GelGlycolysisHumansLipid MetabolismMass SpectrometryMuscle, SkeletalPalmitoyl Coenzyme APhosphofructokinase-1Protein BindingRabbitsThiolester HydrolasesUnilamellar LiposomesAcyl Coenzyme ACalciumCalmodulinLYPLA1 protein, humanPalmitoyl Coenzyme APhosphofructokinase-1Thiolester HydrolasesUnilamellar Liposomes

Identifiers

PMID21258134
PMCPMC3069396
OpenAlexW2075094552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.